Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

This was the stock's second consecutive day of gains.

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

iShares U.S. Pharmaceuticals ETF offers exposure to 42 companies that manufacture prescription or over-the-counter drugs or ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added ...

Eli Lilly has agreed to acquire Scorpion Therapeutics' breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...